478 related articles for article (PubMed ID: 31807871)
1. Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas.
Hirono S; Yamaue H
Surg Today; 2020 Jan; 50(1):50-55. PubMed ID: 31807871
[TBL] [Abstract][Full Text] [Related]
2. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
Fujita Y; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Kobayashi R; Yanagisawa A; Yamaue H
Eur J Surg Oncol; 2022 May; 48(5):1054-1061. PubMed ID: 34933794
[TBL] [Abstract][Full Text] [Related]
3. Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society.
Hirono S; Shimizu Y; Ohtsuka T; Kin T; Hara K; Kanno A; Koshita S; Hanada K; Kitano M; Inoue H; Itoi T; Ueki T; Shimokawa T; Hijioka S; Yanagisawa A; Nakamura M; Okazaki K; Yamaue H
J Gastroenterol; 2020 Jan; 55(1):86-99. PubMed ID: 31463655
[TBL] [Abstract][Full Text] [Related]
4. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
5. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
[TBL] [Abstract][Full Text] [Related]
6. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
[No Abstract] [Full Text] [Related]
8. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
[TBL] [Abstract][Full Text] [Related]
9. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
10. Optimal surveillance of intraductal papillary mucinous neoplasms of the pancreas focusing on remnant pancreas recurrence after surgical resection.
Fuji T; Umeda Y; Takagi K; Yoshida R; Yoshida K; Yasui K; Matsumoto K; Kato H; Yagi T; Fujiwara T
BMC Cancer; 2022 May; 22(1):588. PubMed ID: 35643422
[TBL] [Abstract][Full Text] [Related]
11. Patterns of recurrence and long-term outcomes in patients who underwent pancreatectomy for intraductal papillary mucinous neoplasms with high grade dysplasia: implications for surveillance and future management guidelines.
Blackham AU; Doepker MP; Centeno BA; Springett G; Pimiento JM; Malafa M; Hodul PJ
HPB (Oxford); 2017 Jul; 19(7):603-610. PubMed ID: 28495434
[TBL] [Abstract][Full Text] [Related]
12. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
[TBL] [Abstract][Full Text] [Related]
13. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
Hirono S; Tani M; Kawai M; Ina S; Nishioka R; Miyazawa M; Fujita Y; Uchiyama K; Yamaue H
Arch Surg; 2009 Apr; 144(4):345-9; discussion 349-50. PubMed ID: 19380648
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas based on a long-term follow-up study: proposals for follow-up strategies.
Yogi T; Hijioka S; Imaoka H; Mizuno N; Hara K; Tajika M; Tanaka T; Ishihara M; Shimizu Y; Hosoda W; Yatabe Y; Niwa Y; Yoshimura K; Bhatia V; Fujita J; Yamao K
J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):757-65. PubMed ID: 26148131
[TBL] [Abstract][Full Text] [Related]
16. Carcinoembryonic antigen level in the pancreatic juice is effective in malignancy diagnosis and prediction of future malignant transformation of intraductal papillary mucinous neoplasm of the pancreas.
Hayakawa H; Fukasawa M; Sato T; Takano S; Kadokura M; Shindo H; Takahashi E; Hirose S; Kawakami S; Fukasawa Y; Maekawa S; Inoue T; Yamaguchi T; Nakayama Y; Kawaida H; Kono H; Mochizuki K; Kondo T; Ichikawa D; Enomoto N
J Gastroenterol; 2019 Nov; 54(11):1029-1037. PubMed ID: 31111221
[TBL] [Abstract][Full Text] [Related]
17. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
18. Independent predictors of secondary invasive pancreatic remnant tumors after initial resection of an intraductal papillary mucinous neoplasm: a nationwide large-scale survey in Japan.
Takigawa Y; Kitago M; Matsui J
Surg Today; 2020 Dec; 50(12):1672-1680. PubMed ID: 32661567
[TBL] [Abstract][Full Text] [Related]
19. Surgical indication for intraductal papillary mucinous neoplasm without mural nodule ≥5 mm.
Tsumura A; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yanagisawa A; Yamaue H
Surgery; 2021 Feb; 169(2):388-395. PubMed ID: 32859391
[TBL] [Abstract][Full Text] [Related]
20. Segmental Versus Diffuse Main Duct Intraductal Papillary Mucinous Neoplasm: Examination of Main Pancreatic Duct Morphology and Implications for Malignancy Risk and Extent of Surgical Resection.
Ecker BL; Dickinson SM; Saadat LV; Tao AJ; Pulvirenti A; Balachandran VP; D'Angelica MI; Drebin JA; Kingham TP; Jarnagin WR; Wei AC; Gonen M; Soares KC
Ann Surg; 2023 Jul; 278(1):110-117. PubMed ID: 35950775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
